Top Markets
#1 Cortex Cortex +173.94%
#2 GEKKO GEKKO +50.71%
#3 Audiera Audiera +18.20%
#4 ADO Protocol ADO Protocol +17.37%
#5 Seeker Seeker +14.20%
#6 Pons Pons +14.13%
#7 TENDIES TENDIES +13.73%
#8 Siren Siren +12.81%
#9 o1.exchange o1.exchange +12.30%
#10 Helium Helium +11.78%
Coin of the day
Cortex Cortex
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Classificação em ações #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Preço da ação
$14.07
Última sincronização: 2026-08-28
Valor de mercado
$1.18B
Variação (1 dia)
-4.41%
Variação (1 ano)
145.13%
País
US
Negociar Corvus Pharmaceuticals, Inc. (CRVS)

Categoria

Healthcare
Histórico de dividendos de Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (símbolo da ação: CRVS) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Corvus Pharmaceuticals, Inc. (CRVS) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH